Journal Information
Original article
Available online 15 July 2024
Effectiveness and safety of alirocumab and evolocumab for hypercholesterolemia in a population with high cardiovascular risk
Efectividad y seguridad de alirocumab y evolocumab para la hipercolesterolemia en una población con alto riesgo cardiovascular
Montserrat Boscha,b,c, Immaculada Danésa,b,c,
, Elena Ballarína,c, Patricia Marrerod, Guillem Vancellsd, Ángel Ortiz-Zúñigae, Maria Urquizu-Padillaf, Nuria Rial-Lorenzof, Jordi Lozano-Torresg, David Rodríguez-Lunah, Francesca Filippi-Arriagaa, Antònia Agustía,b,c
Corresponding author
a Clinical Pharmacology Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
b Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Bellaterra, Spain
c Clinical Pharmacology Research Group, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain
d Pharmacy Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
e Endocrinology and Nutrition Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
f Internal Medicine Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
g Cardiology Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
h Neurology Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain